Johnson & Johnson
JOHNSON & JOHNSON (Form: 8-K, Received: 10/19/2010 10:29:28)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549


FORM 8-K


CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
 
Date of report (Date of earliest event reported):
 
October 19, 2010


(Exact name of registrant as specified in its charter)
 
 
New Jersey
I-3215
22-1024240
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)


One Johnson & Johnson Plaza, New Brunswick, New Jersey  08933
 
(Address of Principal Executive Offices)
 (Zip Code)
 
Registrant’s telephone number, including area code:
732-524-0400
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
 
o            Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
o            Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
o            Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
o            Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))


 
 
 
 


Item 2.02                    Results of Operations and Financial Condition
 
On October 19, 2010, Johnson & Johnson issued the attached press release announcing its sales and earnings for the third quarter ended October 3, 2010.
 
Item 9.01                    Financial Statements and Exhibits
 
Exhibit No.                 Description of Exhibit
 
99.15                           Press Release dated October 19, 2010 for the period ended October 3, 2010
 
99.2O                          Unaudited Comparative Supplementary Sales Data and Condensed Consolidated Statement of Earnings for the third quarter
 

 
 
 
 


SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
Johnson & Johnson
 
          (Registrant)        
       
       
       
       
       
Date: October 19, 2010
By:
/s/  Stephen J. Cosgrove
 
   
Stephen J. Cosgrove
Controller
(Principal Accounting Officer)
 
       
       


 
 
 
 

Exhibit 99.15
 

Johnson & Johnson Reports 2010 Third-Quarter Results:

Sales of $15.0 Billion Decreased 0.7% Versus 2009 Third-Quarter;
 EPS of $1.23 increased 2.5% Versus 2009 Third-Quarter

New Brunswick, NJ (October 19, 2010) – Johnson & Johnson today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009.  Operational results increased 0.1% and the negative impact of currency was 0.8%.  Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.
 
Net earnings and diluted earnings per share for the third quarter of 2010 were $3.4 billion and $1.23, respectively, representing increases of 2.2% and 2.5%, as compared to the same period in 2009.
 
The Company raised its earnings guidance for full-year 2010 to $4.70 - $4.80 per share, reflecting recent currency exchange rates.  The Company’s guidance excludes the impact of special items.
 
“We continue to deliver solid earnings while investing in our future through complementary strategic partnerships and acquisitions,” said William C. Weldon, Chairman and Chief Executive Officer. “Our pharmaceutical business has returned to growth this year and we continue to advance our pipeline with promising clinical data in key therapeutic areas.  We are pleased with the strong performance of newly launched products in both our pharmaceutical and medical device and diagnostics businesses.”
 
Worldwide Consumer sales of $3.6 billion for the third quarter represented a decrease of 10.6% versus the prior year consisting of an operational decline of 10.2% and a negative impact from currency of 0.4%.  Domestic sales decreased 24.5%; international sales decreased 0.3%, which reflected an operational increase of 0.4% and a negative currency impact of 0.7%.
 
Positive contributors to operational results were Dabao skin care products, baby care products, and international sales of anti-smoking aids.  Sales were significantly impacted by the previously announced recalls of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare Fort Washington, Pa., facility as well as the currency devaluation in Venezuela.  With respect to the ongoing remediation actions at the Fort Washington facility, Mr. Weldon stated, “We have made considerable progress, and are working diligently to reopen what will be a state of the art facility.  Working across our production network, we have begun restoring the supply of some of the impacted children’s medicines, which will increase in the coming months.”
 
Worldwide Pharmaceutical sales of $5.5 billion for the third quarter represented an increase of 4.7% versus the prior year with operational growth of 5.9% and a negative impact from currency of 1.2%.  Domestic sales increased 6.9%; international sales increased 2.0%, which reflected an operational increase of 4.6% and a negative currency impact of 2.6%. 
 
Several products had strong operational growth including sales of REMICADE® (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA® (darunavir), a treatment for HIV; international sales of RISPERDAL® CONSTA® (risperidone) Long-Acting Treatment, an antipsychotic medication; INTELENCE ® (etravirine), a next generation non-nucleoside reverse transcriptase inhibitor for HIV; and VELCADE® (bortezomib), a treatment for multiple myeloma.
 
Sales growth also includes the strong performance of newly launched products including STELARA TM (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; SIMPONI TM (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; and INVEGA® SUSTENNA TM (paliperidone palmitate), an extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults.
 
During the quarter, the Company submitted new drug applications for TMC 278, a once-daily investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, to the U.S. Food and Drug Administration and the European Medicines Agency.  A supplemental Biologics License Application was also filed in the U.S. to expand the SIMPONI® (golimumab) label in rheumatoid arthritis (RA) to include inhibiting the progression of structural damage in the treatment of moderately to severely active RA.
 
In October, the Company entered into an agreement to acquire all outstanding equity of Crucell N.V. not already owned by the Company for approximately € 1.75 billion in a cash tender offer.  Crucell is a global biopharmaceutical company focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide.
 
Worldwide Medical Devices and Diagnostics sales of $5.9 billion for the third quarter represented an increase of 1.3% versus the prior year consisting of an operational increase of 1.9% and a negative currency impact of 0.6%.  Domestic sales increased 1.2%; international sales increased 1.4%, which reflected an operational increase of 2.6% and a negative currency impact of 1.2%.
 
Primary contributors to operational growth included Ethicon’s surgical care products; Ethicon Endo-Surgery’s minimally invasive and advanced sterilization products; Biosense Webster’s electrophysiology business; and DePuy’s orthopaedic joint reconstruction business.  This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market.
 
During the quarter, the Company completed the acquisition of Micrus Endovascular, a global developer and manufacturer of minimally invasive devices for the treatment of hemorrhagic and ischemic stroke.
 
                   
About Johnson & Johnson
 
Caring for the world, one person at a time…inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

NOTE TO INVESTORS

Johnson & Johnson will conduct a meeting with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com . A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com .
 
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm .  These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises.  Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com
 
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995.  These statements are based on current expectations of future events.  If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections.  Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment.  A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson’s Annual Report on Form 10-K for the fiscal year ended January 3, 2010.  Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov , www.jnj.com or on request from Johnson & Johnson.  Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)

Exhibit 99.2O

 
Johnson & Johnson and Subsidiaries
                             
Condensed Consolidated Statement of Earnings
                             
   
 
   
 
   
 
   
 
       
(Unaudited; in Millions Except Per Share Figures)
 
THIRD QUARTER
 
                               
   
2010
   
2009
   
Percent
 
         
Percent
         
Percent
   
Increase
 
   
Amount
   
to Sales
   
Amount
   
to Sales
   
(Decrease)
 
Sales to customers
  $ 14,982       100.0     $ 15,081       100.0       (0.7 )
Cost of products sold
    4,594       30.7       4,434       29.4       3.6  
Selling, marketing and administrative expenses
    4,709       31.4       4,767       31.6       (1.2 )
Research expense
    1,657       11.1       1,617       10.7       2.5  
Interest (income)expense, net
    95       0.6       114       0.7          
Other (income)expense, net
    (292 )     (2.0 )     (96 )     (0.6 )        
Earnings before provision for taxes on income
    4,219       28.2       4,245       28.2       (0.6 )
Provision for taxes on income
    802       5.4       900       6.0       (10.9 )
Net earnings
  $ 3,417       22.8     $ 3,345       22.2       2.2  
                                         
Net earnings per share  (Diluted)
  $ 1.23             $ 1.20               2.5  
                                         
Average shares outstanding  (Diluted)
    2,786.4               2,793.0                  
                                         
Effective tax rate
    19.0 %             21.2 %                
                                         


 
 
 
 

Johnson & Johnson and Subsidiaries
                             
Condensed Consolidated Statement of Earnings
                             
   
 
   
 
   
 
   
 
       
(Unaudited; in Millions Except Per Share Figures)
 
NINE MONTHS
 
                               
   
2010
   
2009
   
Percent
 
         
Percent
         
Percent
   
Increase
 
   
Amount
   
to Sales
   
Amount
   
to Sales
   
(Decrease)
 
Sales to customers
  $ 45,943     100.0     $ 45,346       100.0       1.3  
Cost of products sold
    13,752     29.9       13,135       29.0       4.7  
Selling, marketing and administrative expenses
    14,244     31.0       14,172       31.3       0.5  
Research expense
    4,862     10.6       4,773       10.5       1.9  
Interest (income)expense, net
    234     0.5       280       0.6          
Other (income)expense, net
    (1,868 )   (4.0 )     (165 )     (0.4 )        
Earnings before provision for taxes on income
    14,719     32.0       13,151       29.0       11.9  
Provision for taxes on income
    3,327     7.2       3,091       6.8       7.6  
Net earnings
  $ 11,392     24.8     $ 10,060       22.2       13.2  
                                       
Net earnings per share  (Diluted)
  $ 4.08           $ 3.61               13.0  
                                       
Average shares outstanding  (Diluted)
    2,792.0             2,787.9                  
                                       
Effective tax rate
    22.6  %           23.5 %                
                                       
Adjusted earnings before provision for taxes and net earnings(A)
     Earnings before provision for taxes on income
$ 13,379  (1)   29.1     $ 13,151       29.0       1.7  
     Net earnings
  $ 10,415  (1)   22.7     $ 10,060       22.2       3.5  
     Net earnings per share  (Diluted)
  $ 3.73  (1)         $ 3.61               3.3  
     Effective tax rate
    22.2  %           23.5 %                
                                       
(1) The difference between as reported earnings and as adjusted earnings before provision for taxes on income, net earnings and net earnings
 
per share (diluted) is the exclusion of income from net litigation of $1,340 million, $977 million and $0.35 per share, respectively.

 
(A) NON-GAAP FINANCIAL MEASURES "Adjusted earnings before provision for taxes on income," "adjusted net earnings," "adjusted net earnings per share (diluted)," and "adjusted effective tax rate" are non-GAAP financial measures and should not be considered replacements for GAAP results. The Company provides earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate on an adjusted basis because management believes that these measures provide useful information to investors. Among other things, they may assist investors in evaluating the Company's results of operations period over period. In various periods, these measures may exclude such items as business development, strategic developments (including restructuring and product line changes), significant litigation, and changes in applicable laws and regulations (including significant accounting or tax matters). Special items may be highly variable, difficult to predict, and of a size that sometimes has substantial impact on the Company's reported results of operations for a period. Management uses these measures internally for planning, forecasting and evaluating the performances of the Company's businesses, including allocating resources and evaluating results relative to employee performance compensation targets. Unlike earnings before provision for taxes on income, net earnings, net earnings per share (diluted), and effective tax rate prepared in accordance with GAAP, adjusted earnings before provision for taxes on income, adjusted net earnings, adjusted net earnings per share (diluted), and adjusted effective tax rate may not be comparable with the calculation of similar measures for other companies. These non-GAAP financial measures are presented solely to permit investors to more fully understand how management assesses the performance of the Company. The limitations of using these non-GAAP financial measures as performance measures are that they provide a view of the Company's results of operations without including all events during a period, such as the effects of an acquisition, merger-related or other restructuring charges, or amortization of purchased intangibles, and do not provide a comparable view of the Company's performance to other companies in the health care industry. Investors should consider non-GAAP financial measures in addition to, and not as replacements for, or superior to, measures of financial performance prepared in accordance with GAAP.

 
 
 
 

Johnson & Johnson and Subsidiaries
             
Supplementary Sales Data
                   
                     
(Unaudited; Dollars in Millions)
THIRD QUARTER
 
         
Percent Change
 
 
2010
 
2009
 
Total
 
Operations
 
Currency
 
Sales to customers by
                   
segment of business
                   
                     
Consumer
                   
    U.S.
$ 1,277   1,691   (24.5 ) %   (24.5 )   -  
    International
  2,290   2,298   (0.3 )   0.4     (0.7 )
    3,567   3,989   (10.6 )   (10.2 )   (0.4 )
                           
Pharmaceutical
                         
    U.S.
  3,054   2,857   6.9     6.9     -  
    International
  2,441   2,392   2.0     4.6     (2.6 )
    5,495   5,249   4.7     5.9     (1.2 )
                           
Med Devices & Diagnostics
                         
    U.S.
  2,800   2,766   1.2     1.2     -  
    International
  3,120   3,077   1.4     2.6     (1.2 )
 
  5,920   5,843   1.3     1.9     (0.6 )
                           
U.S.
  7,131   7,314   (2.5 )   (2.5 )   -  
International
  7,851   7,767   1.1     2.6     (1.5 )
Worldwide
$ 14,982   15,081   (0.7 ) %   0.1     (0.8 )
 

 
 
 

Johnson & Johnson and Subsidiaries
 
Supplementary Sales Data
                             
                               
(Unaudited; Dollars in Millions)
 
NINE MONTHS
 
               
Percent Change
 
   
2010
   
2009
   
Total
   
Operations
   
Currency
 
Sales to customers by
                             
segment of business
                             
                               
Consumer
                             
    U.S.
  $ 4,300       5,125       (16.1 ) %     (16.1 )     -  
    International
    6,680       6,429       3.9       0.5       3.4  
      10,980       11,554       (5.0 )     (6.9 )     1.9  
                                         
Pharmaceutical
                                       
    U.S.
    9,370       9,703       (3.4 )     (3.4 )     -  
    International
    7,316       6,824       7.2       5.3       1.9  
      16,686       16,527       1.0       0.2       0.8  
                                         
Med Devices & Diagnostics
                                       
    U.S.
    8,551       8,194       4.4       4.4       -  
    International
    9,726       9,071       7.2       4.5       2.7  
 
    18,277       17,265       5.9       4.5       1.4  
                                         
U.S.
    22,221       23,022       (3.5 )     (3.5 )     -  
International
    23,722       22,324       6.3       3.7       2.6  
Worldwide
  $ 45,943       45,346       1.3 %     0.0       1.3  
 

 
 
 
 

Johnson & Johnson and Subsidiaries
                             
Supplementary Sales Data
                             
                               
(Unaudited; Dollars in Millions)
 
THIRD QUARTER
 
               
Percent Change
 
   
2010
   
2009
   
Total
   
Operations
   
Currency
 
Sales to customers by
                             
geographic area
                             
                               
U.S.
  $ 7,131       7,314       (2.5 ) %     (2.5 )     -  
                                         
Europe
    3,629       3,879       (6.4 )     1.8       (8.2 )
Western Hemisphere excluding U.S.
    1,424       1,338       6.4       1.7       4.7  
Asia-Pacific, Africa
    2,798       2,550       9.7       4.1       5.6  
International
    7,851       7,767       1.1       2.6       (1.5 )
                                         
Worldwide
  $ 14,982       15,081       (0.7 ) %     0.1       (0.8 )
 

 
 
 
 

Johnson & Johnson and Subsidiaries
                             
Supplementary Sales Data
                             
                               
(Unaudited; Dollars in Millions)
 
NINE MONTHS
 
               
Percent Change
 
   
2010
   
2009
   
Total
   
Operations
   
Currency
 
Sales to customers by
                             
geographic area
                             
                               
U.S.
  $ 22,221       23,022       (3.5 ) %     (3.5 )     -  
                                         
Europe
    11,563       11,522       0.4       2.6       (2.2 )
Western Hemisphere excluding U.S.
    4,079       3,615       12.8       2.5       10.3  
Asia-Pacific, Africa
    8,080       7,187       12.4       5.9       6.5  
International
    23,722       22,324       6.3       3.7       2.6  
                                         
Worldwide
  $ 45,943       45,346       1.3 %     0.0       1.3  
 
 

 
 
 
 

  REPORTED SALES vs. PRIOR PERIOD
  $MM
           
 
THIRD QUARTER
     
% Change
 
2010
2009
Reported
Operational (1)
Currency
 
         
CONSUMER SEGMENT (2)
         
           
SKIN CARE
         
US
       311
      370
(15.9%)
(15.9%)
-     
Intl
       489
      472
3.6%
3.7%
(0.1%)
WW
       800
      842
(5.0%)
(4.9%)
(0.1%)
 
 
 
     
BABY CARE
         
US
       104
      102
2.0%
2.0%
-   
Intl
       462
      442
4.5%
3.6%
0.9%
WW
       566
      544
4.0%
3.3%
0.7%
 
 
 
     
ORAL CARE
         
US
       164
      187
(12.3%)
(12.3%)
-    
Intl
       220
      223
(1.3%)
(2.2%)
0.9%
WW
       384
      410
(6.3%)
(6.8%)
0.5%
 
 
 
     
OTC/NUTRITIONALS
         
US
       438
      732
(40.2%)
(40.2%)
-     
Intl
       671
      666
0.8%
3.5%
(2.7%)
WW
    1,109
   1,398
(20.7%)
(19.4%)
(1.3%)
 
 
 
     
WOMEN'S HEALTH
         
US
       121
      142
(14.8%)
(14.8%)
-     
Intl
       338
      360
(6.1%)
(5.1%)
(1.0%)
WW
       459
      502
(8.6%)
(7.9%)
(0.7%)
 
 
 
     
WOUND CARE/OTHER
         
US
       139
      158
(12.0%)
(12.0%)
-    
Intl
       110
      135
(18.5%)
(18.5%)
0.0%
WW
       249
      293
(15.0%)
(15.0%)
0.0%
 
 
 
     
TOTAL CONSUMER
         
US
    1,277
   1,691
(24.5%)
(24.5%)
-     
Intl
    2,290
   2,298
(0.3%)
0.4%
(0.7%)
WW
    3,567
   3,989
(10.6%)
(10.2%)
(0.4%)
           
Note: See footnotes at end of schedule
         
 

 
 
 
 

  REPORTED SALES vs. PRIOR PERIOD
  $MM
           
 
THIRD QUARTER
     
% Change
 
2010
2009
Reported
Operational (1)
Currency
 

PHARMACEUTICAL SEGMENT   (2) (6)
               
                 
ACIPHEX/PARIET
               
US
116 131 (11.5 %) (11.5 %) -  
Intl
124 130 (4.6 %) 0.8 % (5.4 %)
WW
240 261 (8.0 %) (5.3 %) (2.7 %)
                 
CONCERTA
               
US
214 205 4.4 % 4.4 % -  
Intl
85 79 7.6 % 9.3 % (1.7 %)
WW
299 284 5.3 % 5.8 % (0.5 %)
                 
DURAGESIC/FENTANYL TRANSDERMAL
               
US
42 38 10.5 % 10.5 % -  
Intl
142 168 (15.5 %) (14.2 %) (1.3 %)
WW
184 206 (10.7 %) (9.6 %) (1.1 %)
                 
LEVAQUIN/FLOXIN
               
US
274 294 (6.8 %) (6.8 %) -  
Intl
12 17 (29.4 %) (31.5 %) 2.1 %
WW
286 311 (8.0 %) (8.1 %) 0.1 %
                 
PREZISTA
               
US
102 78 30.8 % 30.8 % -  
Intl
128 73 75.3 % 82.7 % (7.4 %)
WW
230 151 52.3 % 55.9 % (3.6 %)
                 
PROCRIT/EPREX
               
US
204 299 (31.8 %) (31.8 %) -  
Intl
202 243 (16.9 %) (11.9 %) (5.0 %)
WW
406 542 (25.1 %) (22.9 %) (2.2 %)
                 
REMICADE
               
US
857 822 4.3 % 4.3 % -  
US Exports (3)
365 208 75.5 % 75.5 % -  
Intl
7 6 16.7 % 16.7 % 0.0 %
WW
1,229 1,036 18.6 % 18.6 % -  
                 
Note: See footnotes at end of schedule
               

 
 
 
 


  REPORTED SALES vs. PRIOR PERIOD
  $MM
           
 
THIRD QUARTER
     
% Change
 
2010
2009
Reported
Operational (1)
Currency
 

PHARMACEUTICAL SEGMENT  (2) (6) (Continued)
               
                   
RISPERDAL/RISPERIDONE
                 
US
(2 ) 35 (105.7 %) (105.7 %) -  
Intl
123   157 (21.7 %) (22.8 %) 1.1 %
WW
121   192 (37.0 %) (37.9 %) 0.9 %
                   
RISPERDAL CONSTA
                 
US
108   129 (16.3 %) (16.3 %) -  
Intl
270   224 20.5 % 26.6 % (6.1 %)
WW
378   353 7.1 % 11.0 % (3.9 %)
                   
TOPAMAX
                 
US
46   72 (36.1 %) (36.1 %) -  
Intl
81   103 (21.4 %) (18.1 %) (3.3 %)
WW
127   175 (27.4 %) (25.4 %) (2.0 %)
                   
VELCADE
                 
US
-   - -   -   -  
Intl
246   231 6.5 % 10.1 % (3.6 %)
WW
246   231 6.5 % 10.1 % (3.6 %)
                   
OTHER
                 
US
728   546 33.3 % 33.3 % -  
Intl
1,021   961 6.2 % 7.4 % (1.2 %)
WW
1,749   1,507 16.1 % 16.9 % (0.8 %)
                   
TOTAL PHARMACEUTICAL
                 
US
3,054   2,857 6.9 % 6.9 % -  
Intl
2,441   2,392 2.0 % 4.6 % (2.6 %)
WW
5,495   5,249 4.7 % 5.9 % (1.2 %)
                   
MAJOR NEW PHARMACEUTICAL PRODUCTS (4)
                 
                   
INVEGA
                 
US
63   61 3.3 % 3.3 % -  
Intl
35   36 (2.8 %) 1.7 % (4.5 %)
WW
98   97 1.0 % 2.7 % (1.7 %)
                   
Note: See footnotes at end of schedule
                 

 
 
 
 


  REPORTED SALES vs. PRIOR PERIOD
  $MM
           
 
THIRD QUARTER
     
% Change
 
2010
2009
Reported
Operational (1)
Currency
 

MEDICAL DEVICES AND DIAGNOSTICS    (2)
               
                 
CORDIS (5)
               
US
246 233 5.6 % 5.6 % -  
Intl
350 407 (14.0 %) (13.5 %) (0.5 %)
WW
596 640 (6.9 %) (6.6 %) (0.3 %)
                 
DEPUY
               
US
748 740 1.1 % 1.1 % -  
Intl
561 544 3.1 % 4.8 % (1.7 %)
WW
1,309 1,284 1.9 % 2.6 % (0.7 %)
                 
DIABETES CARE
               
US
338 332 1.8 % 1.8 % -  
Intl
275 302 (8.9 %) 0.2 % (9.1 %)
WW
613 634 (3.3 %) 1.0 % (4.3 %)
                 
ETHICON
               
US
480 439 9.3 % 9.3 % -  
Intl
592 580 2.1 % 3.4 % (1.3 %)
WW
1,072 1,019 5.2 % 6.0 % (0.8 %)
                 
ETHICON ENDO-SURGERY
               
US
484 499 (3.0 %) (3.0 %) -  
Intl
653 607 7.6 % 8.4 % (0.8 %)
WW
1,137 1,106 2.8 % 3.3 % (0.5 %)
                 
ORTHO-CLINICAL DIAGNOSTICS
               
US
263 285 (7.7 %) (7.7 %) -  
Intl
235 216 8.8 % 9.2 % (0.4 %)
WW
498 501 (0.6 %) (0.4 %) (0.2 %)
                 
VISION CARE
               
US
241 238 1.3 % 1.3 % -  
Intl
454 421 7.8 % 4.0 % 3.8 %
WW
695 659 5.5 % 3.1 % 2.4 %
                 
TOTAL MEDICAL DEVICES AND DIAGNOSTICS
               
US
2,800 2,766 1.2 % 1.2 % -  
Intl
3,120 3,077 1.4 % 2.6 % (1.2 %)
WW
5,920 5,843 1.3 % 1.9 % (0.6 %)
                 
 Note: See footnotes at end of schedule                

 
 
 
 


  REPORTED SALES vs. PRIOR PERIOD
  $MM
           
 
NINE MONTHS
     
% Change
 
2010
2009
Reported
Operational (1)
Currency
 

CONSUMER SEGMENT (2)
               
                 
SKIN CARE
               
US
1,185 1,204 (1.6 %) (1.6 %) -  
Intl
1,378 1,313 5.0 % 2.0 % 3.0 %
WW
2,563 2,517 1.8 % 0.2 % 1.6 %
                 
BABY CARE
               
US
306 308 (0.6 %) (0.6 %) -  
Intl
1,326 1,233 7.5 % 3.3 % 4.2 %
WW
1,632 1,541 5.9 % 2.5 % 3.4 %
                 
ORAL CARE
               
US
486 549 (11.5 %) (11.5 %) -  
Intl
651 612 6.4 % 1.3 % 5.1 %
WW
1,137 1,161 (2.1 %) (4.8 %) 2.7 %
                 
OTC/NUTRITIONALS
               
US
1,472 2,137 (31.1 %) (31.1 %) -  
Intl
1,985 1,919 3.4 % 0.7 % 2.7 %
WW
3,457 4,056 (14.8 %) (16.1 %) 1.3 %
                 
WOMEN'S HEALTH
               
US
404 443 (8.8 %) (8.8 %) -  
Intl
990 963 2.8 % (0.4 %) 3.2 %
WW
1,394 1,406 (0.9 %) (3.1 %) 2.2 %
                 
WOUND CARE/OTHER
               
US
447 484 (7.6 %) (7.6 %) -  
Intl
350 389 (10.0 %) (13.9 %) 3.9 %
WW
797 873 (8.7 %) (10.4 %) 1.7 %
                 
TOTAL CONSUMER
               
US
4,300 5,125 (16.1 %) (16.1 %) -  
Intl
6,680 6,429 3.9 % 0.5 % 3.4 %
WW
10,980 11,554 (5.0 %) (6.9 %) 1.9 %
                 
Note: See footnotes at end of schedule
               

 
 
 
 



  REPORTED SALES vs. PRIOR PERIOD
  $MM
           
 
NINE MONTHS
     
% Change
 
2010
2009
Reported
Operational (1)
Currency
 

PHARMACEUTICAL SEGMENT   (2) (6)
               
                 
ACIPHEX/PARIET
               
US
356 397 (10.3 %) (10.3 %) -  
Intl
398 387 2.8 % 2.0 % 0.8 %
WW
754 784 (3.8 %) (4.2 %) 0.4 %
                 
CONCERTA
               
US
668 707 (5.5 %) (5.5 %) -  
Intl
283 238 18.9 % 14.3 % 4.6 %
WW
951 945 0.6 % (0.6 %) 1.2 %
                 
DURAGESIC/FENTANYL TRANSDERMAL
               
US
117 163 (28.2 %) (28.2 %) -  
Intl
435 492 (11.6 %) (13.4 %) 1.8 %
WW
552 655 (15.7 %) (17.1 %) 1.4 %
                 
LEVAQUIN/FLOXIN
               
US
926 1,045 (11.4 %) (11.4 %) -  
Intl
31 53 (41.5 %) (44.2 %) 2.7 %
WW
957 1,098 (12.8 %) (12.9 %) 0.1 %
                 
PREZISTA
               
US
290 215 34.9 % 34.9 % -  
Intl
331 198 67.2 % 66.8 % 0.4 %
WW
621 413 50.4 % 50.2 % 0.2 %
                 
PROCRIT/EPREX
               
US
800 950 (15.8 %) (15.8 %) -  
Intl
655 719 (8.9 %) (9.2 %) 0.3 %
WW
1,455 1,669 (12.8 %) (12.9 %) 0.1 %
                 
REMICADE
               
US
2,420 2,330 3.9 % 3.9 % -  
US Exports (3)
1,106 821 34.7 % 34.7 % -  
Intl
19 15 26.7 % 26.7 % 0.0 %
WW
3,545 3,166 12.0 % 12.0 % -  
                 
Note: See footnotes at end of schedule
               

 
 
 
 


  REPORTED SALES vs. PRIOR PERIOD
  $MM
           
 
NINE MONTHS
     
% Change
 
2010
2009
Reported
Operational (1)
Currency
 

PHARMACEUTICAL SEGMENT  (2) (6) (Continued)
 
                   
RISPERDAL/RISPERIDONE
                 
US
(14 ) 223 (106.3 %) (106.3 %) -  
Intl
390   483 (19.3 %) (21.7 %) 2.4 %
WW
376   706 (46.7 %) (48.4 %) 1.7 %
                   
RISPERDAL CONSTA
                 
US
340   386 (11.9 %) (11.9 %) -  
Intl
772   640 20.6 % 20.3 % 0.3 %
WW
1,112   1,026 8.4 % 8.2 % 0.2 %
                   
TOPAMAX
                 
US
162   642 (74.8 %) (74.8 %) -  
Intl
255   317 (19.6 %) (20.5 %) 0.9 %
WW
417   959 (56.5 %) (56.8 %) 0.3 %
                   
VELCADE
                 
US
-   - -   -   -  
Intl
793   652 21.6 % 20.3 % 1.3 %
WW
793   652 21.6 % 20.3 % 1.3 %
                   
OTHER
                 
US
2,199   1,824 20.6 % 20.6 % -  
Intl
2,954   2,630 12.3 % 9.4 % 2.9 %
WW
5,153   4,454 15.7 % 14.0 % 1.7 %
                   
TOTAL PHARMACEUTICAL
                 
US
9,370   9,703 (3.4 %) (3.4 %) -  
Intl
7,316   6,824 7.2 % 5.3 % 1.9 %
WW
16,686   16,527 1.0 % 0.2 % 0.8 %
                   
MAJOR NEW PHARMACEUTICAL PRODUCTS (4)
 
                   
INVEGA
                 
US
200   194 3.1 % 3.1 % -  
Intl
108   93 16.1 % 15.2 % 0.9 %
WW
308   287 7.3 % 7.0 % 0.3 %
                   
Note: See footnotes at end of schedule
                 

 
 
 
 


  REPORTED SALES vs. PRIOR PERIOD
  $MM
           
 
NINE MONTHS
     
% Change
 
2010
2009
Reported
Operational (1)
Currency
 

MEDICAL DEVICES AND DIAGNOSTICS    (2)
               
                 
CORDIS (5)
               
US
762 731 4.2 % 4.2 % -  
Intl
1,161 1,251 (7.2 %) (9.4 %) 2.2 %
WW
1,923 1,982 (3.0 %) (4.4 %) 1.4 %
                 
DEPUY
               
US
2,338 2,268 3.1 % 3.1 % -  
Intl
1,800 1,631 10.4 % 7.3 % 3.1 %
WW
4,138 3,899 6.1 % 4.8 % 1.3 %
                 
DIABETES CARE
               
US
941 908 3.6 % 3.6 % -  
Intl
885 877 0.9 % 2.1 % (1.2 %)
WW
1,826 1,785 2.3 % 2.9 % (0.6 %)
                 
ETHICON
               
US
1,499 1,296 15.7 % 15.7 % -  
Intl
1,852 1,717 7.9 % 5.3 % 2.6 %
WW
3,351 3,013 11.2 % 9.7 % 1.5 %
                 
ETHICON ENDO-SURGERY
               
US
1,474 1,442 2.2 % 2.2 % -  
Intl
2,027 1,794 13.0 % 9.9 % 3.1 %
WW
3,501 3,236 8.2 % 6.5 % 1.7 %
                 
ORTHO-CLINICAL DIAGNOSTICS
               
US
815 846 (3.7 %) (3.7 %) -  
Intl
702 616 14.0 % 11.1 % 2.9 %
WW
1,517 1,462 3.8 % 2.6 % 1.2 %
                 
VISION CARE
               
US
722 703 2.7 % 2.7 % -  
Intl
1,299 1,185 9.6 % 4.9 % 4.7 %
WW
2,021 1,888 7.0 % 4.0 % 3.0 %